Friday pre-open · U.S.-focused thematic intelligence · Paper tracking

Aman's Global Market Intelligence — 2026-09-11

RISK-OFF / CPI BINARY Four straight U.S. declines, oil above $100, the 10-year near 5% and broad Asian losses dominate a modest U.S.-futures bounce. Oracle is a selective exception after stronger cloud results.

Generated 08:36:27 CEST (Europe/Rome); data cutoff 08:36 CEST. U.S. cash/theme prices and European indices are Sep. 10 closes; futures, rates, commodities and Asia are early Sep. 11 indications. Continental Europe opens around 09:00 CEST. This 08:30 Italy report necessarily precedes the U.S. CPI/real-earnings releases at 14:30 CEST and the U.S. cash open at 15:30 CEST.

Executive dashboard

S&P 500 · Sep. 107,591.70−0.58%
Nasdaq Composite26,081.72−0.65%
Dow52,064.10−0.60%
Russell 20002,890.95−1.04%
VIX17.84+8.38%
U.S. 2Y / 10Y · live4.568% / 4.946%+1.8 / +0.2 bp
Dollar index · overnight99.03−0.06%
WTI / Brent · overnight$102.96 / $108.21+0.47% / +0.54%
Gold futures · overnight$4,396.10+0.72%
Nikkei / Hang Seng · live~64,020 / ~24,846−1.92% / −0.44%
Shanghai / Kospi · live~3,896 / ~6,890−0.98% / ~−2.1%
Europe · Sep. 10 closesDAX 25,361 · FTSE 10,609−0.84% / −0.57%
Euro Stoxx 50 · close6,268.97−0.67%; Fri. pre-open
U.S. futures · early Fri.S&P +0.19%Dow +151; Nasdaq-100 <+0.1%

Cross-checks: CNBC Sep. 10 wrap, CNBC Sep. 11 live, CNN market board, Yahoo Markets, CNBC 2Y and CNBC 10Y. Asia values were still moving and are not closes.

1 · Macro

CPI decides the next rates impulse

August CPI arrives 08:30 ET/14:30 CEST. CNBC's Dow Jones poll is +0.4% m/m and +3.4% y/y; those are estimates, not outcomes. Fed-funds futures implied roughly 71%–73% odds of a Sep. 16 hike before CPI. BLS schedule · CME

2 · Oil/rates

Stagflation pressure intensified

Thursday WTI/Brent settled $102.48/$107.63 after +6.7%/+5.9%; Friday indications extended gains. The 10Y was 4.946% and touched 4.979%, while 2Y reached a 52-week high. CNBC live

3 · Cloud

Oracle beat; cash conversion is the catch

ORCL reported $19.35B revenue and $1.92 adjusted EPS, cloud +62%, OCI $7.4B and RPO $664B. But Q1 capex was $28.5B, debt $125B and FCF −$5.4B. Shares were about +4% after hours after falling 5.38% in cash. results

Market drivers

Macro, central banks, rates and geopolitics

  • PPI: August final demand rose 0.4% m/m and 5.4% y/y; goods +1.1%, energy +4.2%, services +0.1%. Less food, energy and trade rose 0.3% m/m/4.7% y/y. BLS primary release
  • Rates: the Treasury's $5.19B long-duration buyback did not stop the 10Y from nearing 5%. CNBC showed 2Y 4.568% and 10Y 4.946% shortly after 08:00 CEST Friday. High-duration growth and leveraged small caps remain exposed. CNBC
  • Fed: Sep. 16 remains live; pre-CPI futures pricing favored a 25 bp hike. Market odds are volatile, not policy guidance. Fed calendar · CME
  • Geopolitics: attacks on vessels near Oman and further Strait of Hormuz claims sustained supply anxiety. Any verified de-escalation could reverse oil, yields and energy equities abruptly. UKMTO · CNBC

Rotation, earnings and unusual moves

  • Breadth/risk: the main U.S. indices fell a fourth day; Russell lost 1.04%, more than large caps, and VIX rose 8.38%. Friday Asia extended de-risking, with Korea/Japan leading losses.
  • AI hardware: NVDA −2.37%, AMD −3.36%, ANET −2.04%, AVGO −0.97% and VRT −5.61%. Rates/oil overwhelmed Wednesday's AMD relative strength; no unsupported company-specific cause is asserted. Yahoo
  • Oracle: cloud infrastructure more than doubled, but PP&E intensity and debt make the post-earnings move a cash-conversion debate—not a clean beat. Software revenue fell about 3%. CNBC/results statement link
  • China AI: Enflame rose 206% on its Shanghai debut after heavily oversubscribed retail demand. This is an IPO scarcity/speculation signal, not evidence that U.S. AI valuations are de-risked. CNBC

Theme dashboards

AI · defensive selective

Cloud demand strong; duration shock stronger

  • Leader/laggard: QCOM +0.27% and GOOGL +0.59% resisted; VRT −5.61%, AMD −3.36%, NVDA −2.37% and ANET −2.04% lagged.
  • Verified catalyst: Oracle OCI was $7.4B and RPO $664B; 850 MW of capacity was delivered in Q1. Full-year capex guidance was unchanged.
  • Risk: ORCL's $28.5B quarterly capex, $125B debt and negative FCF illustrate financing/cash-conversion risk. Oil also raises construction, power and cooling costs.
  • Do not equate backlog with near-term revenue, margin or cash.
Quantum · extreme speculation

Post-catalyst selling persists

  • IONQ fell 3.41% to $36.84; its updated $450M–$460M 2026 revenue outlook includes acquired SkyWater from July 31 and intercompany eliminations—organic quantum economics cannot be inferred. IonQ
  • RGTI fell 0.52% to $15.16 and QBTS 2.69% to $16.66. Rigetti's $100M agreement targets electronics, cryogenics and fabrication, but requires a minority government equity stake. Rigetti
  • Risks: roadmap/fidelity validation, early revenues, cash burn, dilution, acquisitions, liquidity and violent squeeze/gap risk.
Peptide biotech · binary

VKTX has a real but undated Q3 event

  • VKTX fell 1.74% to $32.13. Its ~180-person randomized Phase 1 maintenance study tests weekly, every-other-week and monthly VK2735 after induction; safety, tolerability and PK are objectives, while weight change is exploratory. Data are guided for Q3, not a fixed date. Viking
  • Phase 3 VANQUISH-1/2 are fully enrolled; primary endpoint is percent body-weight change at 78 weeks. Prior Phase 2 injectable data reached 14.7% at 13 weeks; sponsor reporting does not guarantee Phase 3.
  • June 30 cash + short investments were ~$502M versus a $128.0M Q2 net loss; runway is meaningful but burn/dilution remain material.
  • LLY −0.11%, NVO −1.23%, ALT −1.79%. Competition, pricing, manufacturing and tolerability remain decisive.

Ranked ideas — conditional paper setups; fewer is better

1Conditional bullish

ORCL · Oracle (NYSE)

Exchange/risk class: NYSE; mega-cap cloud, high capex/debt/event risk. Classification: post-earnings reclaim. Applicable horizon: day and 1–4 weeks; 3–12+ months only after cash conversion. Direction: uncertain until cash-session confirmation.

Thesis/catalyst/evidence: top/bottom-line beat, OCI +100%+, RPO $664B and FY27 revenue/EPS guidance slightly above consensus; shares +~4% after hours. Counterargument: cash close was $152.94 (−5.38%); Q1 capex $28.5B, debt $125B, FCF −$5.4B and software −3%.

Entry/confirmation: only if regular-hours price holds above ~$159.25 and then reclaims $161.63 with positive cloud breadth. Invalidation/downside: close below $152.94; gaps can bypass. Key risks: debt/credit, construction/power, customer concentration, RPO conversion, margins, capex and CPI. evidence

Thesis Confidence 91
Risk 94
Opportunity 61
1Avoid / failed breakout

VRT · Vertiv (NYSE)

Risk class: large-cap, high-beta AI power/cooling. Classification: avoid; bearish only on confirmation. Applicable horizon: day/1–4 weeks; no structural long-term short. Direction: uncertain; short losses unlimited.

Evidence: $248.13 (−5.61%) after −9.61%, breaking $260 and extending the prior report's failed continuation. Counterargument: no adverse operating release was verified; durable data-center thermal demand and oversold conditions create squeeze risk.

Entry/confirmation: avoid longs; bearish only after a failed $255 reclaim and break below $248. Invalidation/downside: close above $263 cancels; below $240 is next risk zone, not a target. Risks: rebound, project timing, valuation, input/energy costs and macro. Borrow availability/fees unknown. price

Confidence 88
Risk 100
Opportunity 48
2Avoid / speculative fade

IONQ · IonQ (NYSE)

Risk class: high-volatility quantum/acquisition/dilution. Classification: failed post-Investor-Day hold. Applicable horizon: day/1–4 weeks only. Direction: uncertain; unlimited short-loss risk.

Evidence: $36.84 (−3.41%) followed Wednesday's −5.76%; combined guidance includes acquired SkyWater and therefore does not prove organic quantum demand. Counterargument: integration adds foundry scale and roadmap milestones can squeeze bears.

Entry/confirmation: avoid; bearish only after a close below $36.78. Invalidation/downside: regain $38.14, stronger above $40.47; downside below $36 is undefined. Risks: technical success, government awards, acquisition integration, cash burn, dilution and gaps. Borrow data unknown. IonQ

Confidence 90
Risk 100
Opportunity 40
3Avoid / invalidated long

AMD · Advanced Micro Devices (Nasdaq)

Risk class: mega-cap/high-beta semiconductor. Classification: failed relative-strength continuation; avoid, not automatic short. Applicable horizon: day/1–4 weeks. Direction: uncertain.

Evidence: $503.60 (−3.36%) broke the prior $505 invalidation after Wednesday's +3.04%. Counterargument: this may be macro de-risking rather than an operating change; a CPI-driven yield reversal can restore leadership.

Entry/confirmation: no long until a close above $521.10 with positive semiconductor breadth; bearish only below $500 after a failed reclaim. Invalidation/downside: bearish case weakens above $521; below $500 creates gap risk. Risks: valuation, competition, supply/HBM, customer concentration, export controls and rates. price

Confidence 84
Risk 97
Opportunity 43

Watchlist — four evidence-led checkpoints

Relative strength watch

QCOM · Qualcomm (Nasdaq)

Risk/class/horizon: large-cap semiconductor; catalyst reclaim; day/1–4 weeks, long-term after contract economics. Direction: uncertain. Thesis/evidence: $176.88 (+0.27%) resisted the selloff; AWS collaboration remains a demand catalyst. Counter: still below $180.40/$183.49 and warrant/customer concentration matter. Confirmation: close >$180.40, stronger >$183.49. Invalidation/downside: <$172; then $168.74. Risks: concentration, dilution, margins, competition, export controls. Qualcomm · price

Confidence 85
Risk 88
Opportunity 49
Small-cap / extreme quantum

RGTI · Rigetti Computing (Nasdaq)

Risk/class/horizon: small-cap quantum/dilution; catalyst digestion; day/1–4 weeks only. Direction: uncertain. Thesis/evidence: $15.16 (−0.52%); definitive $100M U.S. agreement targets concrete scaling bottlenecks. Counter: minority government equity, milestones and technical execution dilute/condition the benefit. Confirmation: close >$15.81, stronger >$16.40. Invalidation/downside: <$15 then $14.60 risk. Risks: squeeze, dilution, burn, appropriations, roadmap, liquidity. primary release

Confidence 92
Risk 100
Opportunity 42
Clinical-stage binary

VKTX · Viking Therapeutics (Nasdaq)

Risk/class/horizon: small-cap clinical biotech; Q3 catalyst watch; 1–4 weeks around readout and 3–12+ months only after data/regulatory/runway review. Direction: uncertain. Thesis/evidence: $32.13 (−1.74%); maintenance study can differentiate dosing convenience. Counter: ~180 patients, exploratory weight endpoint, no fixed date, pre-revenue and Q2 loss $128M. Confirmation: data must show maintained weight with acceptable safety plus price reclaim >$33.68. Invalidation/downside: poor durability/safety or close <$31.50. Risks: binary efficacy/safety, FDA path, LLY/NVO competition, manufacturing, burn/dilution. Viking

Confidence 89
Risk 100
Opportunity 56
Large-cap peptide

NVO · Novo Nordisk ADR (NYSE)

Risk/class/horizon: large-cap pharma/ADR; stabilization watch; 1–4 weeks and 3–12+ months. Direction: uncertain. Thesis/evidence: $44.01 (−1.23%); commercial semaglutide franchise and Sep. 29 EASD symposium provide information flow. Counter: CagriSema previously missed a Phase 3 primary endpoint, U.S. price reductions begin 2027 and competition is intense. Confirmation: close back above $44.56 then improving relative strength. Invalidation/downside: new weekly low; verify live chart before action. Risks: pricing/access, safety, supply, patent/regulation, FX and LLY/VKTX competition. EASD · SEC filing

Confidence 83
Risk 76
Opportunity 45

Scores are 0–100. Higher Risk means riskier. Thesis Confidence measures evidence quality—not guaranteed probability. Entries are conditional; no fill is assumed.

Changes versus the 2026-09-10 report

  • Risk-off worsened: U.S. indices fell a fourth day; VIX rose to 17.84 and Russell again underperformed.
  • Oil/rates reset higher: WTI jumped from ~$96 to a $102.48 settlement; Brent from ~$101 to $107.63. Live 2Y/10Y are 4.568%/4.946% versus yesterday's official 4.43%/4.83% reference.
  • PPI is known: +0.4% m/m matched consensus, but 5.4% y/y and energy pressure did not calm bonds. Today's CPI replaces PPI as the binary.
  • AMD invalidated: $503.60 broke the prior $505 floor; it moves from #1 conditional bullish to avoid.
  • VRT deteriorated: another −5.61% after −9.61%; bearish/avoid framing remains but squeeze risk is extreme.
  • Oracle becomes the only bullish setup: earnings/cloud beat and +~4% after hours, conditioned on cash-session confirmation because capex/debt/FCF are severe counterweights.
  • Quantum remained weak: IONQ and QBTS extended losses; RGTI held better but did not reclaim its catalyst range.
  • Peptide view upgraded from “no dated binary” to an undated Q3 watch: VKTX's issuer-guided maintenance readout is now inside the remaining quarter, but no release date is asserted.

Important catalysts: next 7–30 days

Sep. 11 · 14:30 CEST — U.S. August CPI + real earnings
Primary duration/Fed catalyst; this report precedes it. Outcome unknown. BLS
Sep. 15–16 — FOMC; decision Sep. 16
Pre-CPI futures implied ~71%–73% chance of a 25 bp hike. The decision, not FedWatch, is authoritative. Fed · CME
Sep. 16 — U.S. import/export prices
Energy, currency and supply-chain inflation checkpoint. BLS
Sep. 18 — U.S. industrial production
Cyclical, power and data-center supply-chain signal. Fed calendar
Sep. 21 — Broadcom company event marker
Information checkpoint, not assumed earnings. Broadcom IR
By Sep. 30 · undated — VKTX maintenance data
Issuer guides Q3. Phase 1 safety/tolerability/PK objectives; body-weight changes exploratory. Timing can slip. Viking
Sep. 28–Oct. 2 — EASD 2026
Novo symposium Sep. 29; watch new semaglutide/amylin evidence without assuming unpublished outcomes. Novo/EASD
Sep. 29 / 30 — IONQ warrants cease trading / expire
Capital-structure flows can distort price. SEC 8-K

Bottom line by horizon

Day trade · Friday

Bias: defensive; wait for CPI and the cash open. ORCL is the sole conditional long above ~$159.25/$161.63. Avoid chasing premarket futures.

Biggest risk: CPI/oil/geopolitical whipsaw. Regime invalidation: 10Y below 4.90%, WTI below $100 and S&P reclaim above 7,636 with positive breadth.

1–4 week swing

Bias: reduced size through FOMC; favor cash-generative quality and confirmed relative strength over high-duration quantum/biotech.

Biggest risk: oil-driven inflation plus a Fed hike. Invalidation: S&P above 7,673 and 10Y below 4.80% on broad participation.

3–12+ month investment

Bias: AI demand is real, but ORCL demonstrates why capex, debt and FCF matter. Quantum needs independent utility/unit economics; peptide needs Phase 3/regulatory and runway proof.

Biggest risk: capital-cost shock, concentration, dilution or technical/clinical failure. Invalidation: durable deterioration in orders, margins and FCF—not one volatile week—would break structural AI theses.

Data quality, retrievals and limitations

  • Live research: more than five independent retrievals covered CNBC live/wrap/quotes, Yahoo chart data, CNN markets, BLS PPI/calendar, company/SEC primary materials for Oracle, Rigetti, IonQ, Viking and Novo, Fed/CME calendars and UKMTO.
  • Cross-checks: Yahoo chart values matched CNBC/CNN U.S. index closes and VIX within rounding; CNBC's wrap matched oil settlements and its live page/quote pages supplied Friday futures and 2Y/10Y. Company facts use issuer releases or linked official statements; Oracle consensus comparisons are LSEG/StreetAccount via CNBC.
  • Timing: Yahoo daily timestamps represented Sep. 10 U.S. closes and early Sep. 11 futures/Asia. Asia was still trading. Europe had not opened at 08:36 CEST; Sep. 10 closes are explicitly labeled.
  • Quote route limitations: the first batched Yahoo request returned HTTP 429, then individual Yahoo chart calls succeeded. Nasdaq quote API timed out for 11 symbols before the command deadline. Treasury CSV timed out in terminal and anti-bot blocked web extraction. Because Yahoo, CNBC and CNN provided working cross-checks, no market datum is declared unavailable and no price was invented.
  • Official-rate distinction: 2Y/10Y are live Tradeweb indications on CNBC, not Treasury end-of-day par yields. Friday quote timestamps were around 02:00–02:35 ET.
  • Commodity precision: WTI/Brent live figures come from CNBC and may differ from Yahoo's refresh/contract. Gold and DXY are Yahoo futures/index indications.
  • Primary-source caution: Oracle's guessed IR slug returned “Page Not Found”; the CNBC article links Oracle's official PRNewswire statement and supplies audited-report context. Rigetti/IonQ/Viking claims remain issuer-reported and forward-looking.
  • No fabrication: no analyst rating/target, unverified valuation multiple, borrow availability/fee, unpublished clinical outcome or guaranteed contract value is asserted. Shorts can lose more than invested.
Risk notice: Initial two weeks are paper-tracking. Research only—not guaranteed, personalized, fiduciary, legal or tax advice. Verify live quotes, liquidity and primary filings before action.